Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure and AF: new clues from inflammation and genes?

NCT ID NCT07152301

Knowledge-focused Sponsor: University of Palermo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study enrolled 164 adults with chronic heart failure, some also with permanent atrial fibrillation. Researchers measured blood markers of inflammation and certain microRNAs (genetic molecules) and used echocardiograms to look at heart structure. The goal was to understand how inflammation and genetics relate to heart remodeling in these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify new markers or targets for better managing heart failure and atrial fibrillation together.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

164 people

The number who actually took part.

Started

Jan 2020

Finished

May 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

consecutive patients with chronic heart failure (CHF) and permanent non-valvular atrial fibrillation (AF), and consecutive patients with CHF, the same risk factors, but sinus rhythm and no prior AF history, admitted to the Internal Medicine and Stroke Care Ward of the "P. Giaccone" Hospital, Palermo

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * ≥18 years * Left ventricular ejection fraction \>40% * New York Heart Association class II-IV symptoms * NT-proBNP ≥600 pg/mL, or ≥900 pg/mL if AF was present on baseline electrocardiography Exclusion Criteria \- Other AF subtypes (paroxysmal, persistent, long-standing persistent) At least one of the following criteria: * Acute heart failure * NYHA IV * NT-proBNP \>4000 pg/mL * Significant valvular disease * Mechanical prosthesis * Cardiovascular implantable devices * Active malignancy * Inflammatory or infectious diseases * Severe renal (eGFR \<30 mL/min/m²) or hepatic failure * Chronic steroid/anti-inflammatory therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (permanent) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation congestive heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (permanent) Congestive heart failure chronic

Contacts and locations

Locations

  • Internal Medicine and Stroke Care Ward, Policlinic Hospital of Palermo, Sicily

    Palermo, PA, 90127, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.